“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
In this video, Neil Mistry, MD, MPH, and Adam B. Murphy, MD, MBA, MSCI, discuss future research and the take-home message from the abstract, “West-African ancestry can aid prediction of high-grade prostate cancer in Black-tailored risk calculator,” which was presented at the North Central Section of the AUA Annual Meeting in Chicago, Illinois. Mistry is a urology resident and Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.